Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13590511 | 0.93 | CHRM3 (0.65) | CHRM3 | |
| SCHEMBL13590443 | 0.93 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL13590469 | 0.92 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL13590438 | 0.91 | CHRM3 (0.70) | CHRM3 | |
| SCHEMBL2508175 | 0.91 | CHRM3 (0.70) | CHRM3 | |
| SCHEMBL27831556 | 0.91 | CHRM3 (0.58) | CHRM3 | |
| SCHEMBL13590365 | 0.91 | CHRM3 (0.61) | CHRM3 | |
| SCHEMBL13590171 | 0.90 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL14001666 | 0.90 | CHRM3 (0.71) | CHRM3 | |
| SCHEMBL649840 | 0.90 | CHRM3 (0.66) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240327352-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | MSN LABORATORIES PRIVATE LTD, R&D CENTER (IN) | 2024-10-03 | — | — | US | disclosed |
| CN-114573500-B | Preparation method of raffinancin intermediate | 扬州中宝药业股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023104920-A1 | CRYSTALLINE ACETONE SOLVATE OF REVEFENACIN | MEDICHEM, S.A. (ES) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023002502-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | MSN LABORATORIES PRIVATE LTD, R&D CENTER (IN) | 2023-01-26 | — | — | WO | disclosed |
| US-20220388981-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11390603-B2 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-07-19 | — | — | US | disclosed |
| CN-114573500-A | Preparation method of lefenacin intermediate | 扬州中宝药业股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087733-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087734-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203137-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203138-A1 | Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885 |
| US-11390603-B2 | Crystalline forms of a biphenyl compound | FFAR1, FFAR4, FFAR3 | CHRM3 1386/4885 |
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885 |
| US-20220388981-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | FFAR1, FFAR4, FFAR3 | CHRM3 1386/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20050203138-A1 | Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20240327352-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | CYP4B1, CYP1B1, KDM4B | CHRM3 357/4885 |
| US-20050203137-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.